Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process
- PMID: 20393191
- DOI: 10.1152/physrev.00023.2009
Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process
Abstract
Alzheimer disease is characterized by the accumulation of abnormally folded protein fragments, i.e., amyloid beta peptide (Abeta) and tau that precipitate in amyloid plaques and neuronal tangles, respectively. In this review we discuss the complicated proteolytic pathways that are responsible for the generation and clearance of these fragments, and how disturbances in these pathways interact and provide a background for a novel understanding of Alzheimer disease as a multifactorial disorder. Recent insights evolve from the static view that the morphologically defined plaques and tangles are disease driving towards a more dynamic, biochemical view in which the intermediary soluble Abeta oligomers and soluble tau fragments are considered as the main mediators of neurotoxicity. The relevance of proteolytic pathways, centered on the generation and clearance of toxic Abeta, on the cleavage and nucleation of tau, and on the general proteostasis of the neurons, then becomes obvious. Blocking or stimulating these pathways provide, or have the potential to provide, interesting drug targets, which raises the hope that we will be able to provide a cure for this dreadful disorder.
Similar articles
-
Proteases and lipoprotein receptors in Alzheimer's disease.Cell Biochem Biophys. 2004;41(1):139-78. doi: 10.1385/CBB:41:1:139. Cell Biochem Biophys. 2004. PMID: 15371644 Review.
-
Amyloid-beta aggregation.Neurodegener Dis. 2007;4(1):13-27. doi: 10.1159/000100355. Neurodegener Dis. 2007. PMID: 17429215 Review.
-
Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35).Exp Neurol. 2010 Jan;221(1):26-37. doi: 10.1016/j.expneurol.2009.09.005. Epub 2009 Sep 12. Exp Neurol. 2010. PMID: 19751725 Review.
-
Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.Neurobiol Aging. 2005 Oct;26(9):1235-44. doi: 10.1016/j.neurobiolaging.2005.05.022. Neurobiol Aging. 2005. PMID: 16023263 Review.
-
Role of melatonin in Alzheimer-like neurodegeneration.Acta Pharmacol Sin. 2006 Jan;27(1):41-9. doi: 10.1111/j.1745-7254.2006.00260.x. Acta Pharmacol Sin. 2006. PMID: 16364209 Review.
Cited by
-
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'.Nat Neurosci. 2015 Jun;18(6):800-6. doi: 10.1038/nn.4018. Nat Neurosci. 2015. PMID: 26007213 Free PMC article. Review.
-
Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.J Med Chem. 2015 Apr 9;58(7):3223-52. doi: 10.1021/acs.jmedchem.5b00191. Epub 2015 Apr 1. J Med Chem. 2015. PMID: 25781223 Free PMC article.
-
Role of aromatic side chains in amyloid β-protein aggregation.ACS Chem Neurosci. 2012 Dec 19;3(12):1008-16. doi: 10.1021/cn300073s. Epub 2012 Sep 24. ACS Chem Neurosci. 2012. PMID: 23259036 Free PMC article.
-
Interplay between α-, β-, and γ-secretases determines biphasic amyloid-β protein level in the presence of a γ-secretase inhibitor.J Biol Chem. 2013 Jan 11;288(2):785-92. doi: 10.1074/jbc.M112.419135. Epub 2012 Nov 14. J Biol Chem. 2013. PMID: 23152503 Free PMC article.
-
Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies.J Biol Chem. 2013 Jan 11;288(2):1295-306. doi: 10.1074/jbc.M112.409250. Epub 2012 Nov 15. J Biol Chem. 2013. PMID: 23155049 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
